Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback